Cancer (Solid Tumors)
15
9
9
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
6.7%
1 terminated out of 15 trials
66.7%
-19.9% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (15)
Steroid Sparing Regimen With Olanzapine and Palonosetron for Emetic Prevention for High Dose Cisplatin
Dietary Supplements Among Cancer Patients: Tolerance, Impact on Medications, and Potential Drug Interactions
SBRT-LATTICE-PATHY
TRTRM (ACTTOP) -Guided Dosing Strategy in Older Patients With Cancer
Is the 1939 Cancer Act Fit for Purpose in the Modern Technology Era?
WellSpan-THRIVE Cancer QOL Study
Comparative Effectiveness of Verbal Instruction Versus Simulation Video Education Among Cancer Patients Undergoing Radiation Therapy
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
Immune Adverse Events Registry in Onco-Hematologic Patients Treated With Immunotherapy
N-Acetylcysteine Roles in Preserving Renal Function Measured by Urinary KIM-1 (Kidney Injury Molecule-1) and Serum Creatinine on Cancer Patients With Cisplatin Based Chemotherapy: A Randomized Placebo-Controlled Trial
Cardiovascular Risk in Children With Chronic Conditions Study
Salutare One Referral Software Impact on Multi-Disciplinary Team (MDT) Meetings Effectiveness and Safety
An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors
A Phase I Study of BMS-690514 in Combination With Paclitaxel and Carboplatin
A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)